Rznomics

SEONGNAM and SEOUL, South Korea, June 15, 2026 Rznomics Inc., a clinical-stage biopharmaceutical company focused on RNA-based gene therapies,...

SEOUL, South Korea, May 8, 2026 Rznomics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...

SAN DIEGO, Calif., April 19, 2026 Rznomics Inc. announced encouraging interim clinical results from its ongoing study of RZ-001,...